BR112021009078A8 - Antagonistas substituídos de receptor de adenosina de aminotriazolopirimidina e aminotriazolopirazina, composições farmacêuticas e seus usos - Google Patents

Antagonistas substituídos de receptor de adenosina de aminotriazolopirimidina e aminotriazolopirazina, composições farmacêuticas e seus usos

Info

Publication number
BR112021009078A8
BR112021009078A8 BR112021009078A BR112021009078A BR112021009078A8 BR 112021009078 A8 BR112021009078 A8 BR 112021009078A8 BR 112021009078 A BR112021009078 A BR 112021009078A BR 112021009078 A BR112021009078 A BR 112021009078A BR 112021009078 A8 BR112021009078 A8 BR 112021009078A8
Authority
BR
Brazil
Prior art keywords
adenosine receptor
aminotriazolopyrazine
aminotriazolopyrimidine
pharmaceutical compositions
receptor antagonists
Prior art date
Application number
BR112021009078A
Other languages
English (en)
Other versions
BR112021009078A2 (pt
Inventor
G Brill Zachary
Ali Amjad
Cumming Jared
Demong Duane
Deng Qiaolin
H Graham Thomas
Kuang Rongze
Lim Yeon-Hee
W Plummer Christopher
Lorena Rico Duque Jenny
Wang Huijun
Zhang Yonglian
Zhao Kake
Original Assignee
Merck Sharp & Dohme
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme
Publication of BR112021009078A2 publication Critical patent/BR112021009078A2/pt
Publication of BR112021009078A8 publication Critical patent/BR112021009078A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

ANTAGONISTAS SUBSTITUÍDOS DE RECEPTOR DE ADENOSINA DE AMINOTRIAZOLOPIRIMIDINA E AMINOTRIAZOLOPIRAZINA, COMPOSIÇÕES FARMACÊUTICAS E SEUS USOS. Em suas muitas modalidades, a presente invenção fornece certos compostos substituídos de aminotriazolopirimidina e aminotriazolopirazina de Fórmula (IA) e Fórmula (IB) ou e sais farmaceuticamente aceitáveis dos mesmos, em que, R1, R2, e R3 são como definidos na presente invenção, composições farmacêuticas compreendendo um ou mais de tais compostos (sozinhos e em combinação com um ou mais outros agentes terapeuticamente ativos), e métodos para a sua preparação e uso, sozinhos e em combinação com outros agentes terapêuticos, como antagonistas de A2a e/ou receptores A2b, e seu uso no tratamento de uma variedade de doenças, condições ou distúrbios que são mediados, pelo menos em parte, pelo receptor de adenosina A2a e/ou receptor de adenosina A2b.
BR112021009078A 2018-11-20 2019-11-15 Antagonistas substituídos de receptor de adenosina de aminotriazolopirimidina e aminotriazolopirazina, composições farmacêuticas e seus usos BR112021009078A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769843P 2018-11-20 2018-11-20
US62/769,843 2018-11-20
PCT/US2019/061622 WO2020106558A1 (en) 2018-11-20 2019-11-15 Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use

Publications (2)

Publication Number Publication Date
BR112021009078A2 BR112021009078A2 (pt) 2021-08-10
BR112021009078A8 true BR112021009078A8 (pt) 2023-02-07

Family

ID=70774154

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021009078A BR112021009078A8 (pt) 2018-11-20 2019-11-15 Antagonistas substituídos de receptor de adenosina de aminotriazolopirimidina e aminotriazolopirazina, composições farmacêuticas e seus usos

Country Status (11)

Country Link
US (1) US20210395255A1 (pt)
EP (1) EP3883575A4 (pt)
JP (1) JP2022507734A (pt)
KR (1) KR20210093964A (pt)
CN (1) CN113015530A (pt)
AU (1) AU2019383948A1 (pt)
BR (1) BR112021009078A8 (pt)
CA (1) CA3119774A1 (pt)
MA (1) MA55142A (pt)
MX (1) MX2021005839A (pt)
WO (1) WO2020106558A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021006329A (es) 2018-11-30 2021-08-11 Merck Sharp & Dohme Llc Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmaceuticas y su uso.
WO2021041360A1 (en) * 2019-08-26 2021-03-04 Incyte Corporation Triazolopyrimidines as a2a / a2b inhibitors
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2284737C (en) 1997-03-24 2007-03-13 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]triazolo[1,5-c]pyrimidine derivatives
KR20040038899A (ko) * 2001-09-28 2004-05-08 교와 핫꼬 고교 가부시끼가이샤 수용체 길항제
PE20030739A1 (es) * 2001-11-30 2003-08-28 Schering Corp Antagonistas del receptor de adenosina a2a
AU2003211993A1 (en) 2002-02-15 2003-09-04 Kyowa Hakko Kogyo Co., Ltd. (1,2,4)TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVES
ATE481985T1 (de) 2002-07-03 2010-10-15 Ono Pharmaceutical Co Immunpotenzierende zusammensetzungen
JPWO2004029056A1 (ja) * 2002-09-24 2006-01-26 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
WO2004072286A1 (ja) 2003-01-23 2004-08-26 Ono Pharmaceutical Co., Ltd. ヒトｐｄ−１に対し特異性を有する物質
EP1615931A1 (en) * 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazines and methods of making and using the same
PT2161336E (pt) 2005-05-09 2013-10-03 Ono Pharmaceutical Co Anticorpos monoclonais humanos para morte programada 1 (pd-1) e métodos de tratamento do cancro utilizando anticorpos anti- pd-1 sozinhos ou em combinação com outros agentes imunoterapêuticos¿
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
ES2616355T3 (es) 2007-06-18 2017-06-12 Merck Sharp & Dohme B.V. Anticuerpos para el receptor humano de muerte programada PD-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
DE102008023801A1 (de) * 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
GB0906579D0 (en) * 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
AU2009288289B2 (en) 2008-08-25 2012-11-08 Amplimmune, Inc. PD-1 antagonists and methods of use thereof
SI2342226T1 (sl) 2008-09-26 2016-11-30 Dana-Farber Cancer Institute Inc. Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
EP3929216A1 (en) 2008-12-09 2021-12-29 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
PE20190262A1 (es) 2011-08-01 2019-02-25 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
TW201803871A (zh) * 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
EP3611174B1 (en) 2017-04-07 2022-06-08 Medshine Discovery Inc. [1,2,4]triazolo[1,5-c]pyrimidine derivative as a2a receptor inhibitor
CN109535161B (zh) 2017-09-22 2021-09-03 江苏恒瑞医药股份有限公司 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用
CN117903140A (zh) 2018-02-27 2024-04-19 因赛特公司 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶

Also Published As

Publication number Publication date
CN113015530A (zh) 2021-06-22
JP2022507734A (ja) 2022-01-18
CA3119774A1 (en) 2020-05-28
BR112021009078A2 (pt) 2021-08-10
KR20210093964A (ko) 2021-07-28
WO2020106558A1 (en) 2020-05-28
MX2021005839A (es) 2021-07-15
EP3883575A1 (en) 2021-09-29
MA55142A (fr) 2022-02-23
EP3883575A4 (en) 2022-06-15
AU2019383948A1 (en) 2021-05-20
US20210395255A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
BR112021009078A8 (pt) Antagonistas substituídos de receptor de adenosina de aminotriazolopirimidina e aminotriazolopirazina, composições farmacêuticas e seus usos
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112019007393A2 (pt) derivados 6,7,8,9-tetra-hidro-3h-pirazolo[4,3-f]isoquinolina úteis no tratamento de câncer
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112017007662A8 (pt) Composto, composição farmacêutica e uso de um composto
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
CL2021001406A1 (es) Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso.
CL2020001762A1 (es) Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464)
BR112015018087A8 (pt) composto, composição farmacêutica e uso
UY28239A1 (es) Derivados de bencenosulfonamida
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112014012628A2 (pt) di-hidrodiazepinocarbazolonas tetra ou pentacíclicas fundidas como inibidoras de parp
BR112015029982A2 (pt) compostos 6,7-di-hidropirazolo[1,5-alfa]pirazin-4(5h)-ona e seu uso como moduladores alostéricos negativos de receptores do mglur2
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
CO2024001922A2 (es) Inhibidores de nlrp3
BR112019000293A2 (pt) formas sólidas de um estimulador de sgc
BR112022010891A2 (pt) Combinação de um antagonista do receptor lpa1 de azetidina com agentes antifibróticos
BR112012017705A2 (pt) derivados de sulfonamidas de 3,4-diarilpirazóis como inibidores da proteína cinase
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BR112022009805A2 (pt) Derivados de piridopirimidinona como antagonistas de ahr
BR112015019802A2 (pt) formulações farmacêuticas de nitrito e usos das mesmas
BR112020020708A8 (pt) Derivados da ureia cíclica fundidã como antagonista crhr2
BR112015031846A8 (pt) derivados de estratrientiazol, seus usos, e composição farmacêutica
BR112018015851A2 (pt) composto, e, medicamento.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]